miR-19a and miR-424 target TGFBR3 to promote epithelial-to-mesenchymal transition and migration of tongue squamous cell carcinoma cells

References

• Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int. 2011;2011:431246. PMID:21660266.
   PubMedGoogle Scholar
• Zhang T, Lubek JE, Salama A, Dyalram D, Liu X, Ord RA. Treatment of cT1N0M0 tongue cancer: outcome and prognostic parameters. J Oral Maxillofac Surg. 2014;72:406-14. doi:10.1016/j.joms.2013.05.028. PMID:24045188.
   PubMed Web of Science ®Google Scholar
• Bilandzic M, Stenvers KL. Betaglycan: a multifunctional accessory. Mol Cell Endocrinol. 2011;339:180-9. doi:10.1016/j.mce.2011.04.014. PMID:21550381.
   PubMed Web of Science ®Google Scholar
• Lambert KE, Huang H, Mythreye K, Blobe GC. The type III transforming growth factor-beta receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell. 2011;22:1463-72. doi:10.1091/mbc.E10-11-0877. PMID:21411633.
   PubMed Web of Science ®Google Scholar
• Meyer AE, Gatza CE, How T, Starr M, Nixon AB, Blobe GC. Role of TGF-beta receptor III localization in polarity and breast cancer progression. Mol Biol Cell. 2014;25:2291-304. doi:10.1091/mbc.E14-03-0825. PMID:24870032.
   PubMed Web of Science ®Google Scholar
• Gatza CE, Oh SY, Blobe GC. Roles for the type III TGF-beta receptor in human cancer. Cell Signal. 2010;22:1163-74. doi:10.1016/j.cellsig.2010.01.016. PMID:20153821.
   PubMed Web of Science ®Google Scholar
• Meng W, Xia Q, Wu L, Chen S, He X, Zhang L, Gao Q, Zhou H. Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts. BMC Cancer. 2011;11:88. doi:10.1186/1471-2407-11-88. PMID:21352603.
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J. Strategies to use microRNAs as therapeutic targets. Best practice & research Clinical endocrinology & metabolism. 2016;30:551-61. doi:10.1016/j.beem.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Jamali Z, Asl Aminabadi N, Attaran R, Pournagiazar F, Ghertasi Oskouei S, Ahmadpour F. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis. Oral Oncol. 2015;51:321-31. doi:10.1016/j.oraloncology.2015.01.008. PMID:25677760.
   PubMed Web of Science ®Google Scholar
• Christopher AF, Gupta M, Bansal P. Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. Gene. 2016;594:30-40. doi:10.1016/j.gene.2016.08.044. PMID:27581787.
   PubMed Web of Science ®Google Scholar
• Nair J, Jain P, Chandola U, Palve V, Vardhan NR, Reddy RB, Kekatpure VD, Suresh A, Kuriakose MA, Panda B. Gene and miRNA expression changes in squamous cell carcinoma of larynx and hypopharynx. Genes Cancer. 2015;6:328-40.
   PubMedGoogle Scholar
• Wang LJ, Zhou X, Wang W, Tang F, Qi CL, Yang X, Wu S, Lin YQ, Wang JT, Geng JG. Andrographolide inhibits oral squamous cell carcinogenesis through NF-kappaB inactivation. J Dent Res. 2011;90:1246-52. doi:10.1177/0022034511418341. PMID:21841043.
   PubMed Web of Science ®Google Scholar
• Li W, Ma J, Ma Q, Li B, Han L, Liu J, Xu Q, Duan W, Yu S, Wang F, et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3K/Akt/NF-kappaB pathway. Curr Med Chem. 2013;20:4185-94. doi:10.2174/09298673113209990251. PMID:23992306.
   PubMed Web of Science ®Google Scholar
• You HJ, How T, Blobe GC. The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis. 2009;30:1281-7. doi:10.1093/carcin/bgp071. PMID:19325136.
   PubMed Web of Science ®Google Scholar
• Luan B, Zhang Z, Wu Y, Kang J, Pei G. Beta-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-kappaB activation. EMBO J. 2005;24:4237-46. doi:10.1038/sj.emboj.7600882. PMID:16308565.
   PubMed Web of Science ®Google Scholar
• Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest. 2007;117:206-17. doi:10.1172/JCI29293. PMID:17160136.
   PubMed Web of Science ®Google Scholar
• Du W, Liang H, Gao X, Li X, Zhang Y, Pan Z, Li C, Wang Y, Liu Y, Yuan W, et al. MicroRNA-328, a Potential Anti-Fibrotic Target in Cardiac Interstitial Fibrosis. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. 2016;39:827-36. doi:10.1159/000447793. PMID:27497782.
   PubMed Web of Science ®Google Scholar
• Jiao J, Zhao X, Liang Y, Tang D, Pan C. FGF1-FGFR1 axis promotes tongue squamous cell carcinoma (TSCC) metastasis through epithelial-mesenchymal transition (EMT). Biochem Biophys Res Commun. 2015;466:327-32. doi:10.1016/j.bbrc.2015.09.021. PMID:26362179.
   PubMed Web of Science ®Google Scholar
• Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007;67:1090-8. PMID:17283142.
   PubMed Web of Science ®Google Scholar
• Li D, Xu D, Lu Z, Dong X, Wang X. Overexpression of transforming growth factor type III receptor restores TGF-beta1 sensitivity in human tongue squamous cell carcinoma cells. Bioscience reports. 2015;35(4):e00243. doi:10.1042/BSR20150141. PMID: 26205654.
   PubMed Web of Science ®Google Scholar
• Lee NY, Kirkbride KC, Sheu RD, Blobe GC. The transforming growth factor-beta type III receptor mediates distinct subcellular trafficking and downstream signaling of activin-like kinase (ALK)3 and ALK6 receptors. Mol Biol Cell. 2009;20:4362-70. PMID:19726563.
   PubMed Web of Science ®Google Scholar
• Sharifi N, Hurt EM, Kawasaki BT, Farrar WL. TGFBR3 loss and consequences in prostate cancer. The Prostate. 2007;67:301-11. PMID:17192875.
   PubMed Web of Science ®Google Scholar
• Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC. Type III TGF-beta receptor enhances colon cancer cell migration and anchorage-independent growth. Neoplasia. 2011;13:758-70. PMID:21847367.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay A, Wang L, Lopez-Casillas F, Mendoza V, Yeh IT, Sun L. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. The Prostate. 2005;63:81-90. PMID:15468171.
   PubMed Web of Science ®Google Scholar
• Sun F, Duan W, Zhang Y, Zhang L, Qile M, Liu Z, Qiu F, Zhao D, Lu Y, Chu W. Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of transforming growth factor, beta receptor III expression. Br J Pharmacol. 2015;172:3779-92. PMID:25884615.
   PubMed Web of Science ®Google Scholar
• You HJ, Bruinsma MW, How T, Ostrander JH, Blobe GC. The type III TGF-beta receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation. Carcinogenesis. 2007;28:2491-500. PMID:17768179.
   PubMed Web of Science ®Google Scholar
• Lee JD, Hempel N, Lee NY, Blobe GC. The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling. Carcinogenesis. 2010;31:175-83. PMID:19955393.
   PubMed Web of Science ®Google Scholar
• Lou J, Zhao D, Zhang LL, Song SY, Li YC, Sun F, Ding XQ, Yu CJ, Li YY, Liu MT, et al. Type III Transforming Growth Factor-beta Receptor Drives Cardiac Hypertrophy Through beta-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II. Hypertension. 2016;68:654-66. PMID:27432858.
   PubMed Web of Science ®Google Scholar
• Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, Pei G. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell. 2004;14:303-17. PMID:15125834.
   PubMed Web of Science ®Google Scholar
• Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A. 2004;101:8603-7. PMID:15173580.
   PubMed Web of Science ®Google Scholar
• Huang L, Wang X, Wen C, Yang X, Song M, Chen J, Wang C, Zhang B, Wang L, Iwamoto A, et al. Hsa-miR-19a is associated with lymph metastasis and mediates the TNF-alpha induced epithelial-to-mesenchymal transition in colorectal cancer. Sci Rep. 2015;5:13350. PMID:26302825.
   PubMed Web of Science ®Google Scholar
• Lu W, Xu Z, Zhang M, Zuo Y. MiR-19a promotes epithelial-mesenchymal transition through PI3K/AKT pathway in gastric cancer. Int J Clin Exp Pathol. 2014;7:7286-96. PMID:25400827.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang J, Yang X, Chen D, Wang L. MiR-424-5p participates in esophageal squamous cell carcinoma invasion and metastasis via SMAD7 pathway mediated EMT. Diagn Pathol. 2016;11:88. PMID:27628042.
   PubMed Web of Science ®Google Scholar
• Xiao X, Huang C, Zhao C, Gou X, Senavirathna LK, Hinsdale M, Lloyd P, Liu L. Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. Arch Biochem Biophys. 2015;566:49-57. PMID:25524739.
   PubMed Web of Science ®Google Scholar
• Banyard J, Chung I, Wilson AM, Vetter G, Le Bechec A, Bielenberg DR, Zetter BR. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep. 2013;3:3151. PMID:24193225.
   PubMed Web of Science ®Google Scholar
• Li J, Yang S, Yan W, Yang J, Qin YJ, Lin XL, Xie RY, Wang SC, Jin W, Gao F, et al. MicroRNA-19 triggers epithelial-mesenchymal transition of lung cancer cells accompanied by growth inhibition. Laboratory investigation; a journal of technical methods and pathology. 2015;95:1056-70. PMID:26098000.
   PubMed Web of Science ®Google Scholar